ПРОГНОСТИЧЕСКИЕ ФАКТОРЫ ОПУХОЛЕВОГО ПРОЦЕССА У БОЛЬНЫХ ДИССЕМИНИРОВАННЫМ КОЛОРЕКТАЛЬНЫМ РАКОМ

New prognostic factors for disseminated colorectal cancer (dCRC) are being investigated in this article.Subjects and methods. In this study we have analyzed three clinical groups. First group – 60 patients with dCRC had not specifical therapy. Second group – 200 patients had specifical therapy, but without identification of prognostic and predictive markers. And third group – 93 patients had individual therapy which was based on prognostic and predictive markers of each patient.Results. Definition of prognostic factors (TS, TP, DPD, Ercc-1, СОХ-2, MSI, KRAS) in patients with dCRC allowed to prescribe optimal specific therapy and improve results of treatment.Conclusion. Investigation of prognostic markers allowed to differentiate prognostic groups among dCRC patients. Investigation of prognostic factors in patients with intermediate prognosis allows to improve treatment outcome and improve number of liver surgery.В статье рассматриваются актуальные вопросы выявления новых факторов в прогнозировании течения и лечения опухолевого процесса при диссеминированном колоректальном раке (дКРР).Материалы и методы. Работа основана на сравнительном анализе лечения 3 групп пациентов: 60 пациентов с дКРР, не получавших лекарственной противоопухолевой терапии, 200 пациентов, получавших лечение без определения предиктивных маркеров чувствительности к цитостатикам, и 93 пациентов, получавших индивидуализированную химиотерапию, основанную на молекулярно-генетическом и иммуногистохимическом анализе опухолевой ткани.Результаты. Определение прогностических факторов (TS, TP, DPD, Ercc-1, СОХ-2, MSI, KRAS) больным с дКРР позволило назначить оптимальную противоопухолевую терапию и улучшить результаты лечения.Заключение. Изучение предиктивных маркеров чувствительности к цитостатикам у пациентов с дКРР позволяет выделить группы промежуточного, неблагоприятного и благоприятного прогноза. В 1-й группе увеличение общей выживаемости путем проведения индивидуализированной цитостатической терапии является перспективной задачей, решение которой позволит увеличить медиану выживаемости пациентов, повысить количество хирургических вмешательств по поводу дКРР

The human body at cellular resolution: the NIH Human Biomolecular Atlas Program

Abstract: Transformative technologies are enabling the construction of three-dimensional maps of tissues with unprecedented spatial and molecular resolution. Over the next seven years, the NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) intends to develop a widely accessible framework for comprehensively mapping the human body at single-cell resolution by supporting technology development, data acquisition, and detailed spatial mapping. HuBMAP will integrate its efforts with other funding agencies, programs, consortia, and the biomedical research community at large towards the shared vision of a comprehensive, accessible three-dimensional molecular and cellular atlas of the human body, in health and under various disease conditions

PROGNOSTIC FACTORS OF TUMORAL PROCESS IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER

New prognostic factors for disseminated colorectal cancer (dCRC) are being investigated in this article.Subjects and methods. In this study we have analyzed three clinical groups. First group – 60 patients with dCRC had not specifical therapy. Second group – 200 patients had specifical therapy, but without identification of prognostic and predictive markers. And third group – 93 patients had individual therapy which was based on prognostic and predictive markers of each patient.Results. Definition of prognostic factors (TS, TP, DPD, Ercc-1, СОХ-2, MSI, KRAS) in patients with dCRC allowed to prescribe optimal specific therapy and improve results of treatment.Conclusion. Investigation of prognostic markers allowed to differentiate prognostic groups among dCRC patients. Investigation of prognostic factors in patients with intermediate prognosis allows to improve treatment outcome and improve number of liver surgery

The human body at cellular resolution: the NIH Human Biomolecular Atlas Program

Transformative technologies are enabling the construction of three dimensional (3D) maps of tissues with unprecedented spatial and molecular resolution. Over the next seven years, the NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) intends to develop a widely accessible framework for comprehensively mapping the human body at single-cell resolution by supporting technology development, data acquisition, and detailed spatial mapping. HuBMAP will integrate its efforts with other funding agencies, programs, consortia, and the biomedical research community at large towards the shared vision of a comprehensive, accessible 3D molecular and cellular atlas of the human body, in health and various disease settings

The human body at cellular resolution: the NIH Human Biomolecular Atlas Program

Transformative technologies are enabling the construction of three dimensional (3D) maps of tissues with unprecedented spatial and molecular resolution. Over the next seven years, the NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) intends to develop a widely accessible framework for comprehensively mapping the human body at single-cell resolution by supporting technology development, data acquisition, and detailed spatial mapping. HuBMAP will integrate its efforts with other funding agencies, programs, consortia, and the biomedical research community at large towards the shared vision of a comprehensive, accessible 3D molecular and cellular atlas of the human body, in health and various disease settings